Lijun Ma1, Qiubing Chen1, Panpan Ma1, Moon Kwon Han2, Zhigang Xu1, Yuejun Kang1, Bo Xiao1,2, Didier Merlin2,3. 1. Institute for Clean Energy & Advanced Materials, Faculty of Materials & Energy, Southwest University, Chongqing 400715, PR China. 2. Institute for Biomedical Sciences, Center for Diagnostics & Therapeutics, Georgia State University, Atlanta, GA 30302, USA. 3. Atlanta Veterans Affairs Medical Center, Decatur, GA 30033, USA.
Abstract
AIM: To enhance the tumor accumulation and targeted drug delivery for colon cancer therapy, iRGD peptide was introduced to the surface of PEGylated camptothecin-loaded nanoparticles (NPs). METHODS: Cellular uptake, targeting specificity, biodistribution and antitumor capacity were evaluated. RESULTS: The functionalization of iRGD facilitated tumor accumulation and cellular uptake of NPs by Colon-26 cells. Furthermore, the resultant iRGD-PEG-NPs remarkably improved the therapeutic efficacy of camptothecin in vitro and in vivo by inducing a higher degree of tumor cell apoptosis compared with PEG-NPs. CONCLUSION: iRGD-PEG-NP is a desired drug delivery system to facilitate the drug accumulation in orthotopic colon tumor tissues and further drug internalization by colon cancer cells.
AIM: To enhance the tumor accumulation and targeted drug delivery for colon cancer therapy, iRGD peptide was introduced to the surface of PEGylated camptothecin-loaded nanoparticles (NPs). METHODS: Cellular uptake, targeting specificity, biodistribution and antitumor capacity were evaluated. RESULTS: The functionalization of iRGD facilitated tumor accumulation and cellular uptake of NPs by Colon-26 cells. Furthermore, the resultant iRGD-PEG-NPs remarkably improved the therapeutic efficacy of camptothecin in vitro and in vivo by inducing a higher degree of tumor cell apoptosis compared with PEG-NPs. CONCLUSION: iRGD-PEG-NP is a desired drug delivery system to facilitate the drug accumulation in orthotopic colon tumor tissues and further drug internalization by colon cancer cells.
Authors: Jason Park; Thomas Mattessich; Steven M Jay; Atu Agawu; W Mark Saltzman; Tarek M Fahmy Journal: J Control Release Date: 2011-06-24 Impact factor: 9.776
Authors: Andrew J Souers; Joel D Leverson; Erwin R Boghaert; Scott L Ackler; Nathaniel D Catron; Jun Chen; Brian D Dayton; Hong Ding; Sari H Enschede; Wayne J Fairbrother; David C S Huang; Sarah G Hymowitz; Sha Jin; Seong Lin Khaw; Peter J Kovar; Lloyd T Lam; Jackie Lee; Heather L Maecker; Kennan C Marsh; Kylie D Mason; Michael J Mitten; Paul M Nimmer; Anatol Oleksijew; Chang H Park; Cheol-Min Park; Darren C Phillips; Andrew W Roberts; Deepak Sampath; John F Seymour; Morey L Smith; Gerard M Sullivan; Stephen K Tahir; Chris Tse; Michael D Wendt; Yu Xiao; John C Xue; Haichao Zhang; Rod A Humerickhouse; Saul H Rosenberg; Steven W Elmore Journal: Nat Med Date: 2013-01-06 Impact factor: 53.440
Authors: Chris Oerlemans; Wouter Bult; Mariska Bos; Gert Storm; J Frank W Nijsen; Wim E Hennink Journal: Pharm Res Date: 2010-08-20 Impact factor: 4.200
Authors: Shanghao Li; Daniel Amat; Zhili Peng; Steven Vanni; Scott Raskin; Guillermo De Angulo; Abdelhameed M Othman; Regina M Graham; Roger M Leblanc Journal: Nanoscale Date: 2016-09-22 Impact factor: 7.790
Authors: Yi Zhong; Tao Su; Qiuxiao Shi; Yanru Feng; Ze Tao; Qiuxia Huang; Lan Li; Liqiang Hu; Shengfu Li; Hong Tan; Shan Liu; Hao Yang Journal: Int J Nanomedicine Date: 2019-11-01
Authors: Jason V Gregory; Padma Kadiyala; Robert Doherty; Melissa Cadena; Samer Habeel; Erkki Ruoslahti; Pedro R Lowenstein; Maria G Castro; Joerg Lahann Journal: Nat Commun Date: 2020-11-10 Impact factor: 14.919